Jun Chen
Corporate Officer/Principal at VISEN Pharmaceuticals
Profile
Jun Chen is currently the Chief Commercial Officer at VISEN Pharmaceuticals since 2021.
Prior to this, he worked at Novo Nordisk China as the Vice President-Marketing from 2002 to 2016.
Jun Chen active positions
Companies | Position | Start |
---|---|---|
VISEN Pharmaceuticals
VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | Corporate Officer/Principal | 2021-03-31 |
Former positions of Jun Chen
Companies | Position | End |
---|---|---|
Novo Nordisk China
Novo Nordisk China Medical SpecialtiesHealth Technology Part of Novo Nordisk Fonden, Novo Nordisk China is a Chinese global biopharmaceutical company headquartered in Copenhagen, Denmark. The company is based in Beijing, China. The company's goal is to drive change in order to overcome serious chronic diseases such as diabetes, obesity, rare blood diseases, and endocrine disorders. | Sales & Marketing | 2016-03-31 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Novo Nordisk China
Novo Nordisk China Medical SpecialtiesHealth Technology Part of Novo Nordisk Fonden, Novo Nordisk China is a Chinese global biopharmaceutical company headquartered in Copenhagen, Denmark. The company is based in Beijing, China. The company's goal is to drive change in order to overcome serious chronic diseases such as diabetes, obesity, rare blood diseases, and endocrine disorders. | Health Technology |
VISEN Pharmaceuticals
VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | Health Technology |
- Stock Market
- Insiders
- Jun Chen